These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20855361)

  • 1. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
    Nelson DL; Phebus LA; Johnson KW; Wainscott DB; Cohen ML; Calligaro DO; Xu YC
    Cephalalgia; 2010 Oct; 30(10):1159-69. PubMed ID: 20855361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.
    Ferrari MD; Färkkilä M; Reuter U; Pilgrim A; Davis C; Krauss M; Diener HC;
    Cephalalgia; 2010 Oct; 30(10):1170-8. PubMed ID: 20855362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
    Choi SK; Green D; Ho A; Klein U; Marquess D; Taylor R; Turner SD
    J Med Chem; 2008 Jun; 51(12):3609-16. PubMed ID: 18507369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.
    Maggioni F; Pini LA; Zanchin G
    Cephalalgia; 2011 Jul; 31(9):1061. PubMed ID: 21511951
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.
    Johnson KW; Schaus JM; Durkin MM; Audia JE; Kaldor SW; Flaugh ME; Adham N; Zgombick JM; Cohen ML; Branchek TA; Phebus LA
    Neuroreport; 1997 Jul; 8(9-10):2237-40. PubMed ID: 9243618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
    Xu YC; Johnson KW; Phebus LA; Cohen M; Nelson DL; Schenck K; Walker CD; Fritz JE; Kaldor SW; LeTourneau ME; Murff RE; Zgombick JM; Calligaro DO; Audia JE; Schaus JM
    J Med Chem; 2001 Nov; 44(24):4031-4. PubMed ID: 11708905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
    John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
    J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
    Cohen ML; Schenck K
    J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of binding, functional activity, and contractile responses of the selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJJC; Zanelli E; Meeus L; Danser AHJ; Gralinski MR; Senese PB; Johnson KW; Kovalchin J; Villalón CM; MaassenVanDenBrink A
    Br J Pharmacol; 2019 Dec; 176(24):4681-4695. PubMed ID: 31418454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
    Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
    J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
    Wainscott DB; Krushinski JH; Audia JE; Schaus JM; Zgombick JM; Lucaites VL; Nelson DL
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):169-77. PubMed ID: 15900510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans.
    Classey JD; Bartsch T; Goadsby PJ
    Brain Res; 2010 Nov; 1361():76-85. PubMed ID: 20833155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.
    Lucaites VL; Krushinski JH; Schaus JM; Audia JE; Nelson DL
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):178-84. PubMed ID: 15900511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT and DA receptor affinity of arylpiperazine derivatives with terminal benzamide fragment.
    Perrone R; Berardi F; Leopoldo M; Tortorella V; Lograno MD; Daniele E; Govoni S
    Farmaco; 1994 Sep; 49(9):567-72. PubMed ID: 7811352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and serotonergic activity of substituted 2, N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT(1B)-like receptor.
    Moloney GP; Martin GR; Mathews N; Milne A; Hobbs H; Dodsworth S; Sang PY; Knight C; Williams M; Maxwell M; Glen RC
    J Med Chem; 1999 Jul; 42(14):2504-26. PubMed ID: 10411472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
    J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT(4) receptor agonists.
    Sonda S; Kawahara T; Katayama K; Sato N; Asano K
    Bioorg Med Chem; 2005 May; 13(9):3295-308. PubMed ID: 15809165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasmiditan: First Approval.
    Lamb YN
    Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.